ChromaDex Receives Positive Opinion on Nicotinamide Riboside as a Novel Food from the World-Leading European Food Safety Auth...
August 07 2019 - 4:10PM
ChromaDex Corp. (NASDAQ:CDXC) today announced that the
European Food Safety Authority (EFSA) has issued a positive opinion
on Nicotinamide Riboside (NR) as a novel food ingredient for use in
a food supplement at a daily serving of 300mg for the healthy adult
population, a critical step in the EU regulatory approval process.
“Safety is paramount for ChromaDex and this positive opinion
from EFSA underscores our depth of science, and is the latest in a
consistently positive series of reviews of NR by authoritative
bodies,” said ChromaDex CEO Rob Fried. “We are diligently
working to complete the regulatory process to bring NR to the
health-conscious people of the EU.”
With the European dietary supplements market expected to reach
$52.9 billion by 2025 according to Grand View Research Inc.,
ChromaDex plans to launch its flagship consumer NR product, Tru
Niagen®, in the EU once the regulatory process is completed.
Cells can use NR, commercially known as Niagen®, to create
nicotinamide adenine dinucleotide (NAD), which is an essential
molecule found in every living cell. NAD plays an essential role in
cellular energy production and supporting cellular repair.
Decreased NAD levels are associated with many age-related declines
in overall health. NIAGEN® is the only commercially available
NR which has twice been successfully reviewed under U.S. Food &
Drug Association's (FDA) new dietary ingredient (NDI) notification
requirement and has also been successfully notified to the FDA as
generally recognized as safe (GRAS).
To date, ChromaDex has invested millions of dollars in safety
and human clinical trials on its patent-protected NR (commercially
known as Niagen) and has entered research agreements with more than
170 leading research institutions, including Dartmouth, the
National Institutes of Health, University of Iowa, and the Scripps
Research Institute.
For additional information on the science supporting Niagen
visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a science-based integrated nutraceutical
company devoted to improving the way people
age. ChromaDex scientists partner with leading
universities and research institutions worldwide to uncover the
full potential of NAD and identify and develop novel, science-based
ingredients. Its flagship ingredient, NIAGEN® nicotinamide
riboside, sold directly to consumers as TRU NIAGEN®, is backed
with clinical and scientific research, as well as extensive IP
protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts
copies of its press releases as well as additional and financial
information about the company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to whether the European
Commission will add NR to the list of authorized substances for
food supplements and the launch of Tru Niagen in the EU. Statements
that are not a description of historical facts constitute
forward-looking statements and may often, but not always, be
identified by the use of such words as "expects", "anticipates",
"intends", "estimates", "plans", "potential", "possible",
"probable", "believes", "seeks", "may", "will", "should", "could"
or the negative of such terms or other similar expressions. More
detailed information about ChromaDex and the risk factors
that may affect the realization of forward-looking statements is
set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2018, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted
by ChromaDex to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement
and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a
portion of the grant funding as a collaborator for the study.
ChromaDex Media Contact: Alex Worsham, Director
of Strategic Partnerships 310-388-6706 ext. 689
alexw@chromadex.com
ChromaDex Investor Relations Contact: Brianna
Gerber, Sr. Director of FP&A and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024